Method for making dendritic cell vaccines from embryonic stem cells
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Aug 10, 2005
filing date -
Aug 10, 2004
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
This disclosure provides a technology for making a dendritic cell vaccine suitable for high volume manufacturing and distribution. Human stem cells are differentiated in a multi-step protocol to generate cell populations bearing a dendritic cell phenotype. The cells are loaded by pulsing with a specific tumor antigen, or by activation of an inducible transgene. The primed dendritic cells are powerful components of a vaccination strategy to elicit an immune response against tumor-associated antigens like telomerase. Vaccines and reagent combinations prepared according to this invention can be used on demand as off-the-shelf products for treating cancer.
First Claim
Other Claims data not available